SCHEMBL4548696

SCHEMBL4548696

COc1cc2c(Oc3ccc4c(C(=O)NC5CC5)cccc4c3)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.75
TEK Q02763 16/20 0.75
AURKA O14965 15/20 0.75
MET P08581 14/20 0.75
LCK P06239 12/20 0.75
AURKB Q96GD4 9/20 0.75
LYN P07948 2/20 0.75
ABL1 P00519 1/20 0.75
FGR P09769 1/20 0.75
FLT1 P17948 2/20 0.61
STK10 O94804 1/20 0.59
CSF1R P07333 1/20 0.59
RET P07949 1/20 0.59
PDGFRB P09619 1/20 0.59
KIT P10721 1/20 0.59
AXL P30530 1/20 0.59
TIE1 P35590 1/20 0.59
FLT4 P35916 1/20 0.59
FLT3 P36888 1/20 0.59
MERTK Q12866 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748792 0.89 KDR (0.60) KDRTEKAURKAMETLCK
SCHEMBL4548830 0.88 KDR (0.88) KDRTEKAURKAMETLCK
SCHEMBL4548697 0.87 FLT3 (0.68) KDRTEKAURKAMETLCK
SCHEMBL2746021 0.87 KDR (1.00) KDRTEKAURKAMETLCK
SCHEMBL2747397 0.86 KDR (0.75) KDRTEKAURKAMETLCK
SCHEMBL14018164 0.86 KDR (0.63) KDRTEKAURKAMETLCK
SCHEMBL4548694 0.86 KDR (0.75) KDRTEKAURKAMETLCK
SCHEMBL2747456 0.86 KDR (0.61) KDRTEKAURKAMETLCK
SCHEMBL4548695 0.85 KDR (0.59) KDRTEKAURKAMETLCK
SCHEMBL4548708 0.85 KDR (0.67) KDRTEKAURKAMETLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885TEK 184/4885AURKA 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.